terça-feira, 24 de fevereiro de 2009

Outcomes in Adolescents with Postural Orthostatic Tachycardia Syndrome Treated with Midodrine and [beta]-Blockers.

LAI, CINDY, FISCHER, PHILIP, BRANDS, CHAD, FISHER, JENNIFER, PORTER, CO-BURN, DRISCOLL, SHERILYN, GRANER, KEVIN

Pacing & Clinical Electrophysiology. 32(2):234-238, February 2009.

Background: Postural orthostatic tachycardia syndrome (POTS) is associated with debilitating fatigue, dizziness, and discomfort in previously healthy adolescents. The effects of medical therapy have not been well studied in this patient population. This study assessed the relative efficacy and impact of drug therapy on the functioning and quality of life in adolescents with POTS.

Methods: A retrospective, single center, chart review analysis with a follow-up written survey was conducted on a group of 121 adolescents who had undergone autonomic reflex screening at the Mayo Clinic from 2002 to 2005 as part of an evaluation for possible POTS.

Results: Of 121 surveys sent, 47 adolescents returned a completed survey. In this cohort of patients, the two most commonly prescribed drug therapies were midodrine (n = 13) and [beta]-blockers (n = 14). Patients in the midodrine group were comparable to patients in the [beta]-blocker group in gender, age, pretreatment postural heart rate changes, and months from initial evaluation to survey completion. More patients treated with a [beta]-blocker reported improvement after visiting Mayo Clinic (100% vs 62%, P = 0.016) and more attributed their progress to medication (63.6% vs 36.4%, P = 0.011) than did those treated with midodrine.

Conclusion: Treatment with both midodrine and [beta]-blockers was associated with overall improvement in POTS patients' general health; however, adolescents taking [beta]-blockers were more likely than those taking midodrine to credit the role of medications in their improvement.

Copyright (C) 2009 Blackwell Publishing Ltd.

Statin Use and Ventricular Arrhythmias During Clinical Treadmill Testing.

DEWEY, FREDERICK, PEREZ, MARCO, HADLEY, DAVID, FREEMAN, JAMES, WANG, PAUL, ASHLEY, EUAN, MYERS, JONATHAN, FROELICHER, VICTOR

Background: Premature ventricular complexes (PVCs) during exercise are associated with adverse prognosis, particularly in patients with intermediate treadmill test findings. Statin use reduces the incidence of resting ventricular arrhythmias in patients with coronary artery disease; however, the relationship between statin use and exercise-induced ventricular arrhythmias has not been investigated.

Methods and Results: We evaluated the association between statin use and PVCs in 1,847 heart-failure-free patients (mean age 58, 95% male) undergoing clinical exercise treadmill testing between 1997 and 2004 in the VA Palo Alto Health Care System. PVCs were quantified in beats per minute and frequent PVCs were defined as PVC rates greater than the median value (0.43 and 0.60 PVCs per minute for exercise and recovery, respectively). Propensity-adjusted logistic regression was used to evaluate the odds of developing PVCs during exercise and recovery periods associated with statin use. There were 431 subjects who developed frequent PVCs during exercise and 284 subjects had frequent recovery PVCs. After propensity score adjustment, subjects treated with statins (n = 145) had 42% lower odds of developing frequent PVCs during exercise (odds ratio [OR] 0.58, 95% confidence interval [CI] 0.37-0.93) and 44% lower odds of developing frequent PVCs during recovery (OR 0.56, 95% CI 0.30-0.94). These effects were not modified by age, prior coronary disease, hypercholesterolemia, exercise-induced angina, or exercise capacity.

Conclusions: Statin use was associated with reduced odds of frequent PVCs during and after clinical exercise testing in a manner independent of associations with coronary disease or ischemia in our study population.

((J Cardiovasc Electrophysiol, Vol. 20, pp. 193-199, February 2009)

Copyright (C) 2009 Blackwell Publishing Ltd.

Influence of Ventriculoatrial Timing on Hemodynamics and Symptoms During Supraventricular Tachycardia.

LAURENT, GABRIEL, LEONG-POI, HOWARD, MANGAT, IQWAL, KORLEY, VICTORIA, PINTER, ARNOLD, HU, XUDONG, SO, PETSY, RAMADEEN, ANDREW, DORIAN, PAUL

Journal of Cardiovascular Electrophysiology. 20(2):176-181, February 2009.

Abstract




Aims: Patients with reentrant supraventricular tachycardia (SVT) are often highly symptomatic and the mechanism of symptoms is not well understood. We hypothesized that variation in ventriculoatrial interval (QRS to P) modulates the left atrial pressure and symptoms during tachycardia.

Methods and Results: Three hundred twenty-six patients awaiting electrophysiological study completed a questionnaire regarding "neck pounding" or "shirt flapping" during tachycardia. Mean left atrial pressure was measured during simulated atrioventricular reentry tachycardia (AVRT) and atrioventricular nodal reentry tachycardia (AVNRT) in 18 patients. Pulmonary venous flow reversal was assessed using transesophageal echocardiography in 12 dogs when pacing at 220 bpm with different VA delays (0 to 250 ms). "Shirt flapping" is present more often during AVNRT than during AVRT (58.6% vs 43.8%, respectively, P < clear="both">
Conclusion: "Shirt flapping" and "neck pounding" frequently occur during AVNRT. LA contractions during AV valve closure increase left atrial pressure and may explain differences in certain symptoms between AVNRT and AVRT.

Copyright (C) 2009 Blackwell Publishing Ltd.

The Trials and Tribulations of Fibrillation Ablation

Editorial Comment
J Cardiovasc Electrophysiol, Vol. pp. 1-2

While this analogy is perhaps somewhat harsh, it expresses the low opinion held by many physicians concerning the technique of metanalysis. Others view the metanalysis as a practitioner's “wild card”—if the results of the metanalysis support your position on some question, it was a “carefully done, well-conducted metanalysis.” If, on the other hand, its major conclusions are at odds with your position, the response is, “well, it was just a metanalysis.” The purpose of the metanalysis is to pool the data from several relatively small studies that may individually lack adequate subject numbers to show statistical significance, in order to discern if questions posed in the small studies can be more firmly answered, with greater statistical power.

The metanalysis regarding catheter ablation of atrial fibrillation (AF) by Nair et al. in this issue of the Journal 1 will likely share the fate of former metanalyses (extolled by some, derided by others). However, given the material with which they had to work, the authors did as good an analysis as the data would permit. The usual impediments to this type of review (differences in study design, patient cohorts, endpoints) are perhaps amplified in the AF population because of the different presentations of AF as well as the great variety of ablation procedures performed and lack of consistent outcome measures. The authors acknowledge these shortcomings in their article. One of the most striking features of the article is their finding that, after an exhaustive search of the literature, only six studies fulfilled their appropriately stringent inclusion criteria—encompassing all of 693 patients (despite the fact that thousands of patients undergo these procedures annually). Although their analysis revealed that ablation does confer benefit and the studies were consistent in this result, it is a sad commentary on our field that so little objective data are available to support such a frequently performed procedure. In addition, real-world results may not be as good as those found in Nair et al.'s analysis, since among the studies they surveyed, the ablation procedures were performed at relatively high-volume institutions by talented and seasoned practitioners.

The fact that a metanalysis concerning catheter ablation for atrial fibrillation (AF) is even relevant should be concerning to those of us who perform these procedures, since it indicates that there are no large-scale clinical trials showing that what we are doing offers better results than medical therapy. Seasoned practitioners all “know” that catheter ablation ameliorates symptoms in patients with AF (if not “curing” them), but how broadly does this apply, and how certain is the result? For years, based on small studies, we “knew” that serial drug testing was good treatment for ventricular tachycardia, that elimination of premature ventricular complexes in patients with structural heart disease was a worthy goal, and that dual-site atrial pacing prevented AF. While individual patients may have benefited from each of these supposed good therapies, all have gone by the wayside after larger trials showed their shortcomings when applied to larger groups of patients.

Even the best-intended therapies often have unanticipated adverse consequences—one need look no further for examples than AF ablation, with the potential for pulmonary vein stenosis, left atrial-esophageal fistula, phrenic and vagal nerve trunk damage. Thus, we urgently need large scale, well-controlled trials to start addressing just how valuable AF ablation is, especially in certain subsets such as patients with very large left atria and those with minimally symptomatic AF. Cost analysis between separate treatment approaches is another important issue, as raised by the authors. While such large trials cannot address every question about AF ablation, they may provide information that can serve to help generate new hypotheses and questions for further study. One of the most difficult aspects of treating patients with AF is their almost universal desire to discontinue anticoagulant therapy after what appears to be a successful ablation. Although there are some data in the literature that bear on this question,2 it is not definitive and, clearly, further study is needed.

Many physicians who perform AF ablation have longed for a good, solid, multicenter clinical trial that answers once and for all (at least, for the momentary present since the field is changing rapidly) the question of just how much benefit patients receive on their investment in this procedure. After all, it is the patient who assumes the procedural risks, misses work or family duties, and has some monetary exposure—shouldn't they have some assurance that the procedure yields superior results to medical therapy in their situation? For many physicians, the complexities of designing such a trial are just too daunting—what type of patients to enroll, what procedure to use to ablate AF, what procedural and follow-up endpoints (and duration) are needed to give a meaningful answer. Considerable variation in these parameters can often be seen between operators even within the same institution. Certainly these are thorny problems, but we should start somewhere. The Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial,3 comparing catheter ablation to medical therapy with a total mortality primary endpoint, is one such attempt at a large-scale trial in AF ablation and has completed its pilot enrollment; the full-scale trial will hopefully begin enrollment in 2009. We urgently need the results of this and similar long-overdue trials to practice data-driven medicine of the highest quality for the benefit of our patients. Let's not have to rely on metanalysis, no matter how well-done, to justify our current practices.

References

1. Nair GM, Nery PB, Diwakaramenon S, Healey JS, Connolly SJ, Morillo CA: A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. J. Cardiovasc Electrophysiol 2008; DOI: 10.1111/j.1540-8167.2008.01285.x. [Context Link]

2. Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, Reich S, Igic P, Elmouchi D, Tschopp D, Wimmer A, Dey S, Crawford T, Pelosi F Jr, Jongnarangsin K, Bogun F, Morady F: Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006;114:759–765. Ovid Full Text Bibliographic Links [Context Link]

3. Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ: HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007;4: 816–861. [Context Link]

A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation.

Source Journal of Cardiovascular Electrophysiology. 20(2):138-144, February 2009.

Abstract


Introduction: Atrial fibrillation (AF) is the most frequent arrhythmia seen in clinical practice. Until recently, antiarrhythmic medications have been the only commonly employed treatment for maintaining sinus rhythm. However, antiarrhythmic medications have a modest long-term efficacy and the potential for serious side effects. Radiofrequency (RF) ablation is now emerging as a viable alternative to antiarrhythmic medications in maintaining sinus rhythm in patients with AF. Several randomized trials comparing RF ablation with antiarrhythmic medications have now been published.

Objectives: To perform a systematic review of published randomized trials comparing RF ablation with antiarrhythmic medications in the treatment of AF.

Methods: A systematic review of the literature was performed and two authors independently abstracted the data from trials. A statistical analysis was performed using Comprehensive Meta-Analysis Software(TM) (BIOSTAT, Englewood, NJ, USA).

Results: A total of six trials were identified. Overall, RF ablation reduced the risk of AF recurrence by 65% at 1 year compared with antiarrhythmic medications.

Conclusions: In selected patients with AF, RF ablation reduced the risk of AF recurrence at 1 year by 65% compared with antiarrhythmic medications.

(J Cardiovasc Electrophysiol, Vol. 20, pp. 138-144, February 2009)

Copyright (C) 2009 Blackwell Publishing Ltd.

quinta-feira, 12 de fevereiro de 2009

Usefulness of Baseline Electrocardiographic QRS Complex Pattern to Predict Response to Cardiac Resynchronization

Date Posted: 2/4/2009
Author(s): Adelstein EC, Saba S.
Citation: Am J Cardiol 2009;103:238-242.
Clinical Trial: No
Study Question: Do patients with right bundle branch block (RBBB) or pacing-induced left bundle branch block (LBBB) benefit from cardiac resynchronization therapy (CRT) as often as patients with LBBB?
Methods: This was a retrospective study of 636 patients (mean age 67 years) with heart failure, QRS duration >120 ms, and an ejection fraction (EF) ≤35% who underwent CRT. Patients were classified as having an intrinsic LBBB (n = 407), pacing-induced LBBB (n = 160), or RBBB (n = 59). The outcomes were symptomatic response to CRT, echocardiographic response, and a composite endpoint of death, heart transplantation, or ventricular assist device implantation.
Results: The mean pre-CRT QRS duration was significantly longer in the paced group (199 ms) than in the LBBB (166 ms) and RBBB (168 ms) groups. During a mean follow-up of approximately 3 years, the composite endpoint was more frequent in the RBBB group (77%) than in the LBBB group (60%) and paced group (55%). After controlling for baseline differences, survival in the RBBB group was 41% lower than in the other groups. Symptomatic improvement after CRT was more frequent in patients with LBBB (59%) and in the paced patients (46%) than in the patients with RBBB (14%). The relative improvement in EF was greater in the LBBB group (23%) than in the RBBB group (3%).
Conclusions: RBBB predicts a poor response to CRT.
Perspective: A post-hoc analysis of randomized clinical trials of CRT also indicated that patients with RBBB generally do not respond to CRT. Despite the fact that RBBB may mask a left-sided ventricular conduction delay that results in dyssynchrony, at present there is inadequate evidence to support the use of CRT in patients with RBBB.  Fred Morady, M.D., F.A.C.C.

segunda-feira, 9 de fevereiro de 2009

Endurance Sport Practice as a Risk Factor for Atrial Fibrillation and Atrial Flutter

Lluís Mont; Roberto Elosua; Josep Brugada

Europace.  2009;11(1):11-17.  ©2009 Oxford University Press
Posted 02/05/2009

Abstract

Although the benefits of regular exercise in controlling cardiovascular risk factors have been extensively proven, little is known about the long-term cardiovascular effects of regular and extreme endurance sport practice, such as jogging, cycling, rowing, swimming, etc. Recent data from a small series suggest a relationship between regular, long-term endurance sport practice and atrial fibrillation (AF) and flutter. Reported case control studies included less than 300 athletes, with mean age between 40 and 50. Most series recruited only male patients, or more than 70% males, who had been involved in intense training for many years. Endurance sport practice increases between 2 and 10 times the probability of suffering AF, after adjusting for other risk factors. The possible mechanisms explaining the association remain speculative. Atrial ectopic beats, inflammatory changes, and atrial size have been suggested. Some of the published studies found that atrial size was larger in athletes than in controls, and this was a predictor for AF. It has also been shown that the left atrium may be enlarged in as many as 20% of competitive athletes. Other proposed mechanisms are increased vagal tone and bradycardia, affecting the atrial refractory period; however, this may facilitate rather than cause the arrhythmia. In summary, recent data suggest an association between endurance sport practice and atrial fibrillation and flutter. The underlying mechanism explaining this association is unclear, although structural atrial changes (dilatation and fibrosis) are probably present. Larger longitudinal studies and mechanistic studies are needed to further characterize the association to clarify whether a threshold limit for the intensity and duration of physical activity may prevent AF, without limiting the cardiovascular benefits of exercise.

Introduction

Regular and extreme endurance sport practice (jogging, cycling, swimming, etc.) has become very popular even among adults in their forties. The benefits of regular exercise in controlling cardiovascular risk factors have been extensively proved,[1-4] and therefore cardiologists widely recommend regular exercise to improve cardiovascular health. However, recent data have documented a relationship between long-term endurance sport practice or rigorous occupational physical activity and atrial fibrillation (AF) and atrial flutter.[5-10] The association is being increasingly recognized and has raised the need for larger epidemiological studies.[11-13] On the other hand, moderate physical activity may indeed decrease the risk for AF in older adults.[14]

Atrial fibrillation is the most common arrhythmia and has a great impact in morbidity and mortality.[15,16] The current increase in incidence is not fully explained by the aging population or higher prevalence of newly described risk factors such as obesity.[17,18] Therefore, non-identified factors apart from family history[19] may be present. Atrial fibrillation is associated with a number of cardiac and extracardiac diseases, such as hypertension, structural heart disease, and hyperthyroidism. However, in a significant proportion of patients, its aetiology remains unknown.[20] This condition, called lone AF (LAF), is defined as AF in patients younger than age 60 and without any identifiable aetiologic factor. The prevalence of LAF ranges from 2-10% in the general population to 30% in studies performed in patients with paroxysmal AF who seek medical attention.[21,22] Lone atrial fibrillation is commonly associated with atrial flutter, as described by Coumel;[23] therefore, they seem to be two expressions of the same underlying condition.

The aim of this review is to analyse the evidence of the association between LAF and endurance sport practice or occupational physical activity, the pathophysiological mechanisms underlying this association, the clinical characteristics of this arrhythmia, and the available therapeutic options.

Atrial Fibrillation and Endurance Sport Practice

Although the presence of AF in athletes had been described previously,[24,25] to the best of our knowledge Karjalainen et al.[5] were the first, in 1998, to publish a longitudinal prospective study establishing a relationship between endurance sport practice and AF. They studied a series of orienteers (an endurance sport often practiced in Scandinavia). After 10 years of follow-up, AF incidence among orienteers was 5.3%, when compared with 0.9% among the control subjects. Therefore, the incidence of AF was unusually high in a series of middle-aged endurance sport practitioners without predisposing factors. Furthermore, the two patients with AF in the control group were also involved in endurance practice. The odds ratio for LAF associated with vigorous exercise was 5.5 (95% confidence interval: 1.3-24.4) in this study ( Table 1 ).

Our interest in the subject also began in 1998. A retrospective analysis of our series of LAF patients seen at the outpatient arrhythmia clinic showed that the proportion of regular sport practice among men with LAF was much higher than among men from the general population (63 vs. 15%).[6] In that series, a rather lax definition of sport practice was used (more than 3 h a week at the moment of evaluation), but in fact most patients had been involved in endurance sport practice for more than 10 years, with much higher participation levels in the past. Some of them had already limited their practice as a consequence of the arrhythmia.

The same population of LAF patients was analysed in a case-control study with two age-matched controls for each case from the general population.[7] The analysis showed that the current sport practice increased the risk of developing LAF more than five times (OR 5.06 (1.35-19), a result that is within the range reported by Karjalainen et al.[5] It is noteworthy that the association of current sport practice with LAF was observed at more than 1500 lifetime hours of sport practice, suggesting the existence of a threshold point. Of course, this threshold point should be interpreted with caution, and probably points out the pattern of the association (i.e. number of hours of sport practice and a posterior plateau) rather than the exact threshold point ( Table 1 ).

To confirm the association between endurance sports and AF in a longitudinal manner, our group undertook a study that included 183 individuals who ran the Barcelona Marathon in 1992 and 290 sedentary healthy individuals included in the REGICOR study.[9,26] After 10 years of follow-up, the annual incidence rate of LAF among marathon runners and sedentary men was 0.43/100 and 0.11/100, respectively. Endurance sport practice was associated with a higher risk of incident LAF in the multivariable age- and blood pressure-adjusted Cox regression models (hazard ratio = 8.80; 95% confidence interval: 1.26-61.29). The main limitation of this study was the small number of events observed during follow-up (n = 9 among marathon runners and n = 2 among sedentary men). Nevertheless, the results were consistent with previous observations.[5,7]

Recently, Baldesberger et al.[27] published similar data in a study of 64 former Swiss professional cyclists who completed the Tour de Suisse professional cycling race at least once during the years 1955-1975. These athletes were compared with a control group of 62 male golfers who had never performed high-endurance training. Individuals were matched for age, weight, hypertension, and cardiac medication. The mean age at examination was 66 ± 7 years. Former cyclists showed a lower heart rate and a higher incidence of AF or atrial flutter (10 vs. 0%, P <>et al.[5] or by Molina et al.[9] is probably explained because this study population was older. These data suggest that incidence of AF and flutter further increases with aging in athletes, as with any kind of AF.

In contrast with these previous studies, Pellicia et al.[28] reported that the incidence of LAF among competitive athletes was uncommon and similar to that observed in the general population. However, the study was performed in young athletes at the moment of highest activity. Studies supporting the association have been performed in middle-aged individuals, after many years of sport practice.

Atrial Flutter and Endurance Sport Practice

Most of the described series include patients suffering concomitant AF and atrial flutter, suggesting that endurance sports contribute to the development of both arrhythmias. For example, Baldesberger et al.[27] found a higher incidence of flutter than AF in their series of veteran cyclists, although the authors did not describe whether these were common or atypical flutter episodes. Heidbuchel et al.[8] found that endurance athletes had a higher recurrence rate for AF than did controls (Figure 1). The authors conclude that endurance sport practice increases the risk of suffering AF after common flutter ablation. Hoogsteen et al.[29] found that 10% of athletes with AF also suffer episodes of atrial flutter. These observations suggest that both arrhythmias often co-exist in endurance athletes, and common flutter may be secondary to right atrial dilatation as a consequence of volume overload.

Figure 1. 

Patients with a history of endurance sports before ablation (n = 31) developed significantly more atrial fibrillation than controls or those with a history of other type o sports activity after flutter ablation (reproduced from reference 8, with permission).

     

Atrial Fibrillation and Occupational Physical Activity

These studies seem to have established that long-lasting endurance sport practice increases the risk of LAF. Vigorous physical activity associated with occupational activities may theoretically pose a similar risk. Data from the recently published GIRAFA study[10] appear to confirm this theory. The prospective GIRAFA study is conducted in consecutive patients with LAF recruited at the emergency room. In this case-control study, 107 LAF patients were compared with age- and sex-matched healthy controls. Total hours of physical activity (during work or leisure time) were collected with a detailed and validated questionnaire. For each physical activity, the following variables were recorded: age started, age ended, months per year, days per week, and hours per day. Subjects were asked to classify the intensity of each physical activity in four levels: sedentary, light, moderate, and heavy. The results showed that the moderate and heavy physical activity, whether sport- or job-related, increased the risk of suffering AF. In multivariable analysis, physical activity and atrial size were independent predictors for the development of AF, even after normalizing by body surface area (BSA) and height. In contrast with these observations, The Danish Diet Cancer and Health Study, conducted in a population of 19 593 men and 18 807 women with a mean age of 56 (range 50-65), failed to demonstrate any association between physical activities during working hours and risk of hospitalization with a diagnosis of AF or flutter.[30] This discrepancy may be due to the limited categorization and quantification of physical activity, compared to the much deeper analysis in the GIRAFA study. Further epidemiological studies, with a detailed quantification of work-associated physical activity, are needed to clarify this potential association.

It is interesting to note the GIRAFA study's association of height and atrial size (absolute and normalized) with AF. In understanding the male predominance observed in AF, sex may indeed be secondary to that association. Hanna et al.[31] had already reported a relationship between stature and AF prevalence in patients with left ventricular (LV) dysfunction (Figure 2).

Figure 2. 

Thin-plate smoothing spline regression results assessing the non-linear relation between height and occurrence of lone atrial fibrillation (left panel), and the linear relation between left atrial (LA) diameter and occurrence of lone atrial fibrillation (right panel) (reproduced from reference 9, with permission).

     

Pathophysiology of Sport-related Atrial Fibrillation

What is the possible link between physical activity and AF? Several mechanisms may be acting together. It is well accepted that arrhythmias depend on triggers, substrates, and modulators, and these factors may be present in relation to physical activity (Figure 3).

Figure 3. 

Classical triangle of Coumel suggesting possible etiopathogenic factors influencing the development of atrial fibrillation in athletes.

     

Triggers: Role of Atrial Ectopy

Atrial ectopy, particularly pulmonary vein ectopy, has been shown to be the trigger in most episodes of paroxysmal AF.[32] Atrial and ventricular ectopy may be increased as a consequence of physical activity.[27,33] Moreover, increased ventricular ectopy in elite athletes is reversible after detraining.[34] Therefore, increased ectopy may be one of the mechanisms explaining the increased risk for AF associated with sport practice, provided that this ectopy acts upon an appropriate substrate. However, a recent paper by Baldesberger et al.[27] did not find an increased incidence of atrial ectopy, despite increases in ventricular ectopy and VT runs in former professional cyclists. Therefore, the hypothesis of increased atrial ectopy as an explanation for the association between sports and AF cannot be adequately sustained with currently available data.

Modulators: Influence of Autonomic Nervous System

Why does an apparently healthy individual start suffering from AF? Coumel[35] studied the influence of autonomic innervations in the appearance of AF and atrial flutter. He reported: 'Vagally mediated AF occurs more frequently in men than in women, with a ratio of ~4:1'. The age at which the first symptoms appear is classically between 40 and 50 years [sic]. The essential feature is the occurrence of the AF at night, often ending in the morning. Rest, the postprandial state (particularly after dinner) and alcohol are also precipitating factors [sic][36] (Figure 4). The author concluded that although AF occurred in a vagal context, an unidentified substrate probably existed. However, he did not establish a relationship between these episodes of AF and sport practice.

Figure 4. 

Twenty-four hours recording of heart rate showing a nocturnal episode of atrial fibrillation.

     

Experimental data show that increased vagal tone shortens and increases the dispersion of the atrial refractory period, creating the conditions for re-entry.[37-39] However, vagal AF is considered to be a rare presentation of AF. This is probably due to the lack of systematic inquiry with patients. According to the GIRAFA study,[10] vagal AF is the rule rather than the exception in LAF patients (~70% of consecutive LAF patients had vagal AF). Therefore, the increased vagal tone induced by endurance sport practice may indeed facilitate the appearance of AF. In fact, heart rate is still lower in former athletes many years after cessation of professional training than in controls, as recently shown by Baldesberger et al.[27]

Another interesting hypothesis recently raised by Swanson[40] in a review of the existing literature is that gastroesophageal reflux, which indeed has been proven to produce AF and vagal reflexes, may be the link between increased AF and exercise. However, this hypothesis has not yet been properly investigated.

Arrhythmia Substrate

Whether there is a structural substrate in LAF is still a matter of debate. In patients with hypertension or structural heart disease, it seems that AF is the consequence of structural changes in the atria (dilatation and fibrosis) secondary to chronic volume and pressure overload. It is therefore plausible that long-term endurance sport practice or occupational physical activity may induce structural changes in the atrium (enlargement, fibrosis) that may create a favourable substrate for the disease. In fact, Frustaci et al.[41] found structural changes in a series of 12 patients with paroxysmal, recurrent, drug refractory LAF. The authors described inflammatory lymphonomonuclear infiltrates, compatible with myocarditis, in 66% of patients; a non-inflammatory cardiomyopathic process in 17%; and patchy fibrosis in the remaining 17%. Whether the data correspond to a highly selected population cannot be definitively ruled out, but 100% of patients showed histological changes. On the other hand, these changes could have been produced by repetitive episodes of AF.

A recent review of the literature by Swanson[42] shows that excessive endurance exercise and overtraining can lead to chronic systemic inflammation and there is a relationship between AF and C-reactive protein. Anti-inflammatory agents have been reported to lower C-reactive protein and ameliorate AF. Whether inflammation may be mediated by the renin-angiotensin system and a sustained increase in catecholamines remains to be elucidated. At present, no published studies combine these three concepts: AF, inflammation, and exercise. Additional studies are needed.

Although the underlying mechanism for structural changes is not clear, recent echocardiographic data suggest that structural remodelling is often present in the atrium of elite athletes without AF. Pelliccia et al.[28] recently published a study that describes the remodelling induced by exercise in elite sport athletes. Their data showed that those involved in regular endurance practice have a larger atrium when compared with sedentary controls. Furthermore, a significant proportion (20%) showed enlarged atria according to established normal values.

GIRAFA study data[10] showing that patients with LAF had a larger atrium when compared with controls suggest that subtle structural changes at the atrial level may account for the appearance of AF. The study further showed that patients with a first episode of AF had the same atrial size when compared with those suffering recurrences. Therefore, it seems that structural changes were present before onset of AF. On the other hand, patients with AF had larger LV mass, even after normalizing for BSA. This further supports the idea that exercise also had some repercussions in the ventricles, but without differences in diastolic function index when compared with controls. Although diastolic dysfunction has been proposed as the mechanistic background for atrial enlargement, it seems that volume and pressure overload act directly in the atrium, even before acting at the ventricular level.

A recent case-control study by Lindsay and Dunn[43] involving 45 veteran athletes showed biochemical evidence of a disruption of the collagen equilibrium that would favour fibrosis. Athletes showed an increase in three collagen markers, plasma PICP, CITP, and TIMP-1, when compared with sedentary controls. The authors suggest that fibrosis occurs as part of the hypertrophic process in veteran athletes. Furthermore, an increase in fibrosis at the atrial and right ventricular level has been shown in a model of endurance exercise in rats.[44]

Another factor that has been suggested as a cause of AF is the use of anabolic steroids. Although some isolated case reports show a link between AF and steroids,[45,46] the cases have presented in young athletes, at the moment of maximal physical activity, whereas AF in endurance sports seems to occur in middle-aged men, years after cessation of professional competitive or maximal activity. Therefore, although anabolic steroids may have a role in the genesis of AF, it is probably marginal. If atrial enlargement and fibrotic changes precede AF, what is the role of vagal tone and pulmonary veins in premature beats? It could be that in AF secondary to physical activity, vagal tone and ectopics may act more as a trigger and modulator than as the cause itself.

Clinical Characteristics of Sport-related Atrial Fibrillation

The typical clinical profile of sport-related AF or atrial flutter is a middle-aged man (in his forties or fifties) who has been involved in regular endurance sport practice since his youth (soccer, cycling, jogging, and swimming), and is still active. This physical activity is his favourite leisure time activity and he is psychologically very dependent on it. The AF is usually paroxysmal with crisis, initially very occasional and self limited, and progressively increasing in duration. Characteristically, AF episodes occur at night or after meals. As many as 70% of patients may suffer predominantly vagal AF.[10] They almost never occur during exercise. This makes the patient reluctant to accept a relationship between the arrhythmia and sport practice, particularly since his physical condition is usually very good. The crises typically become more frequent and prolonged over the years and AF becomes persistent. Progression to permanent AF has been described by Hoogsteen et al. in 17% of individuals in an observational series. In the GIRAFA study, 43% presented persistent AF.[10,29] The AF crisis frequently coexists with common atrial flutter in many patients, as previously discussed.

Therapeutic Measures

Although data on the reversibility of arrhythmia upon sport cessation are scarce, Furlanello et al.[25] have described a good response to sport abstinence in top-level athletes with AF. Our observations, although not systematic, suggest that limiting physical activity seems to significantly reduce the number of crises, particularly in those with recent onset and minimally dilated atrium. However, these patients are very dependent on physical activity and it is difficult for them to follow this advice. Previous studies have demonstrated the reversibility of hypertrophic changes at the ventricular level in the hearts of athletes. Biffi et al.[34] also showed a very significant decrease in ventricular ectopy upon sport cessation. Therefore, while awaiting more definitive data, it seems advisable to significantly reduce endurance sport practice in these cases.

The possible long-term role of drugs (ACE inhibitors, angiotensin inhibitors, or beta-blockers) in preventing cardiac hypertrophy remains to be elucidated, although angiotensin blockers do seem to play a role in improving the results of cardioversion or AF ablation.[47,48] In terms of arrhythmia prevention, patients with recurrent episodes have been treated with flecainide and diltiazem, preventing 1:1 atrial flutter secondary to flecainide with good results. Some of them had undergone AF ablation with a success rate similar to patients not involved in endurance sport practice (authors' unplublished observations). In patients with predominant atrial flutter, ablation of the flutter is frequently associated with a higher incidence of AF recurrences, as pointed out by Heidbuchel et al.[8] A recent study by Furlanello et al.[49] described a highly successful ablation, with 90% success after a mean of two ablation procedures in a series of 20 athletes, without major complications. Apparently, the goal of the ablation was to allow rather veteran athletes (44 ± 13 years) to re-initiate their competitive activity. The reported series may represent a selected series of patients, since most of them presented exercise-induced AF, in contrast with the reported prevalence of vagal AF among endurance athletes. Although ablation seems to be quite effective, endurance sport cessation associated with drug therapy seems to us a more suitable approach as an initial therapy, particularly in non-professional, veteran athletes.

Conclusions

Vigorous physical activity, whether related to long-term endurance sport practice or to occupational activities, seems to increase the risk for recurrent AF. The underlying mechanisms remain to be elucidated, although structural atrial changes (dilatation and fibrosis) are probably present. There is a relationship between accumulated hours of practice and AF risk. Further studies are needed to clarify whether a threshold limit for the intensity and duration of physical activity may prevent AF, without limiting the cardiovascular benefits of exercise.


Table 1. Summary of the Published Studies Analyzing the Relationship Between Atrial Fibrillation and Atrial Flutter and Endurance Sport Practice


Studies Type of study Men (%) Age Type of sport(s) Cases/controls Odds ratio (CI) for AF in athletes
Karjalainen et al.[5] Longitudinal case/control 100 47 ± 5 runners, 49 ± 5 controls Orienteers 262/373 5.5 (1.3-24.4)
Mont et al.[6] Retrospective compared to general population 100 44 ± 13 athletes, 49 ± 11 non-athletes Endurance sports >3 h per week 70 lone AF 61% in male athletes with lone AF
Elosua et al.[7] Retrospective case/control 100 41 ± 13 AF pat, 44±11 controls Endurance sports: current practice and >1500 accumulated hours of practice 51/109 2.87 (1.39-7.05) adjusted for age and hypertension
Heidbuchel et al.[8] Case/control in patients undergoing flutter ablation 83 53 ± 9 sports, 60 ± 10 controls Cycling, running, or swimming >3 h per week 31/106 1.81 (1.10-2.98)
Molina et al.[9] Longitudinal case/control 100 39 ± 9 runners, 50 ± 13 sedentary Marathon runners 252/305 8.80 (1.26-61.29) adjusted for age and blood pressure
Baldesberger et al.[27] Longitudinal case/control 100 67 ± 7 cyclist, 66 ± 6 golfers Cyclists 134/62 10% AF in cyclists, 0% AF in controls
Mont et al.[10], GIRAFA study Prospective case/control 69 48 ± 11 Endurance sports 107/107 7.31 (2.33-22.9), >550 h of accumulated heavy physical activity




    References

    1. Morris JN, Everitt MG, Pollard R, Chave SP, Semmence AM. Vigorous exercise in leisure-time: protection against coronary heart disease. Lancet (1980) 2:1207-10.
    2. Kujala UM, Kaprio J, Taimela S, Sarna S. Prevalence of diabetes, hypertension, and ischemic heart disease in former elite athletes. Metabolism (1994) 43:1255-60.
    3. Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA (1996) 276:205-10.
    4. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation (2003) 107:3109-16.
    5. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ (1998) 316:1784-5.
    6. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, et al. Long-lasting sport practice and lone atrial fibrillation. Eur Heart J (2002) 23:477-82.
    7. Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E, et al. Sport practice and the risk of lone atrial fibrillation: a case-control study. Int J Cardiol (2006) 108:332-7.
    8. Heidbuchel H, Anne W, Willems R, Adriaenssens B, Van de WF, Ector H. Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. Int J Cardiol (2006) 107:67-72.
    9. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace (2008) 10:618-23.
    10. Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent B, Sitges M, et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace (2008) 10:15-20.
    11. Taggar JS, Lip GY. Risk predictors for lone atrial fibrillation. Europace (2008) 10:6-8.
    12. Lampert R. Atrial fibrillation in athletes: toward more effective therapy and better understanding. J Cardiovasc Electrophysiol (2008) 19:463-5.
    13. Schoonderwoerd BA, Smit MD, Pen L, Van Gelder I. New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation. Europace (2008) 10:668-73.
    14. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults. The Cardiovascular Health Study. Circulation (2008) 118:800-7.
    15. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol (2006) 48:854-906.
    16. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 98:946-52.
    17. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J (1996) 131:790-5.
    18. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 292:2471-7.
    19. Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 336:905-11.
    20. Leather RA, Kerr CR. Atrial fibrillation in the absence of overt cardiac disease. In: Atrial fibrillation: Mechanisms and Management. (1992) New York: Raven Press. 93-108.
    21. Planas F, Romero-Menor C, Vazquez-Oliva G, Poblet T, Navarro-Lopez F. Natural history of and risk factors for idiopathic atrial fibrillation recurrence (FAP Registry). Rev Esp Cardiol (2006) 59:1106-12.
    22. Levy S, Maarek M, Coumel P, Guize L, Lekieffre J, Medvedowsky JL, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation (1999) 99:3028-35.
    23. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J (1994) 15:9-16.
    24. Coelho A, Palileo E, Ashley W, Swiryn S, Petropoulos AT, Welch WJ, et al. Tachyarrhythmias in young athletes. J Am Coll Cardiol (1986) 7:237-43.
    25. Furlanello F, Bertoldi A, Dallago M, Galassi A, Fernando F, Biffi A, et al. Atrial fibrillation in elite athletes. J Cardiovasc Electrophysiol (1998) 9:S63-8.
    26. Masia R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, et al. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. REGICOR Investigators. J Epidemiol Commun Health (1998) 52:707-15.
    27. Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J (2008) 29:71-8.
    28. Pelliccia A, Maron BJ, Di Paolo FM, Biffi A, Quattrini FM, Pisicchio C, et al. Prevalence and clinical significance of left atrial remodeling in competitive athletes. J Am Coll Cardiol (2005) 46:690-6.
    29. Hoogsteen J, Schep G, Van Hemel NM, Van Der Wall EE. Paroxysmal atrial fibrillation in male endurance athletes. A 9-year follow up. Europace (2004) 6:222-8.
    30. Frost L, Frost P, Vestergaard P. Work related physical activity and risk of a hospital discharge diagnosis of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Occup Environ Med (2005) 62:49-53.
    31. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Beshai JF, et al. The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. J Am Coll Cardiol (2006) 47:1683-8.
    32. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med (1998) 339:659-66.
    33. Bjornstad H, Storstein L, Meen HD, Hals O. Ambulatory electrocardiographic findings in top athletes, athletic students and control subjects. Cardiology (1994) 84:42-50.
    34. Biffi A, Maron BJ, Verdile L, Fernando F, Spataro A, Marcello G, et al. Impact of physical deconditioning on ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol (2004) 44:1053-8.
    35. Coumel P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur Heart J (1994) 15:9-16.
    36. Coumel Ph. Neural aspects of paroxysmal atrial fibrillation. In: Atrial Fibrillation: Mechanisms and Management—Falk RG, Podrid PhJ, eds. (1992) Raven Press. 109-25.
    37. Hoff HE, Geddes LA. Cholinergic factor in auricular fibrillation. J Appl Physiol (1955) 8:177-92.
    38. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J (1959) 58:59-70.
    39. Alessi R, Nusynowitz M, Abildskov JA, Moe GK. Nonuniform distribution of vagal effects on the atrial refractory period. Am J Physiol (1958) 194:406-10.
    40. Swanson DR. Running, esophageal acid reflux, and atrial fibrillation: a chain of events linked by evidence from separate medical literatures. Med Hypotheses (2008) 71:178-85.
    41. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation (1997) 96:1180-4.
    42. Swanson DR. Atrial fibrillation in athletes: implicit literature-based connections suggest that overtraining and subsequent inflammation may be a contributory mechanism. Med Hypotheses (2006) 66:1085-92.
    43. Lindsay MM, Dunn FG. Biochemical evidence of myocardial fibrosis in veteran endurance athletes. Br J Sports Med (2007) 41:447-52.
    44. Benito B, Gay-Jordi G, Serrano A, Sirenko V, Tamborero D, Berruezo A, et al. Chronic exercise induces atrial and right ventricular fibrosis in a rat model. (Abstract Supplement). Eur Heart J (2008) 29:740.
    45. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med (1999) 17:851-7.
    46. Lau DH, Stiles MK, John B, Shashidhar, Young GD, Sanders P. Atrial fibrillation and anabolic steroid abuse. Int J Cardiol (2007) 117:e86-e87.
    47. Anne W, Willems R, Van der MN, Van de WF, Ector H, Heidbuchel H. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart (2004) 90:1025-30.
    48. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation (2002) 106:331-6.
    49. Furlanello F, Lupo P, Pittalis M, Foresti S, Vitali-Serdoz L, Francia P, et al. Radiofrequency catheter ablation of atrial fibrillation in athletes referred for disabling symptoms preventing usual training schedule and sport competition. J Cardiovasc Electrophysiol (2008) 19:457-62.
    Acknowledgements

    We thank Elaine M. Lilly, PhD, Writer's First Aid and Neus Portella, Research Assistant for editing the mauscript.